Daiken Biomedical officially listed on September 9 at an underwriting price of NT$158 per share. Chairman Zhang Chia-Ming stated that the company plans to launch at least four new products in the fourth quarter. Coupled with the promotional boost from major shopping festivals such as Double 11 and Double 12, the company expects strong operational growth for the year.

The public underwriting before the listing attracted approximately 460,000 participants, with a total market fund freeze of NT$72.69 billion. The winning rate was 1.44%, setting a new record this year for both the number of applicants and the amount of frozen funds.

Zhang Chia-Ming emphasized that Daiken Biomedical will actively expand into international markets. The company established a subsidiary in Japan this year, which operated on a trial basis during the first half of the year and is expected to start contributing revenue in the second half. Analysts estimate that the company could achieve a local listing in Japan after 2027.

Zhang noted that the Japanese market will be the primary overseas revenue contributor next year, with a focus on fish oil and probiotic products. In the second half of next year, the company aims to leverage Japan’s tariff advantages to export products to Southeast Asian markets including Vietnam, Indonesia, Thailand, and Malaysia.

Daiken Biomedical recorded NT$789 million in revenue and NT$143 million in net profit after tax in the first half of 2025, with earnings per share of NT$2.40, representing year-on-year growth of 50.57% in revenue and 4,098.5% in net profit. Over the past five years, the company achieved a compound annual growth rate (CAGR) of 88%, demonstrating strong growth momentum. With the upcoming peak e-commerce season in the second half of the year, the company expects this growth momentum to continue.

Chairman Zhang added that the company’s core product lines include supplements for cardiovascular health, vision care, and probiotics. As a leading domestic brand in the health food sector, Daiken Biomedical leverages extensive R&D experience to provide professional health management solutions.

Resource: 大研生醫9日掛牌上市 明年強攻日本市場